Price To Earnings Ratio 73.71 | Sector PE 40.01 |
PB Ratio 10.79 | Sector PB 6.78 |
EPS 82.68 | Dividend Yield 0.52 |
Today's Volume 668.601 K | 5 Day Avg. Volume 398.342 K |
PEG Ratio 2.00 | Market Cap. ₹ 1,60,000.00 Cr. |
Divi's Laboratories Limited is an Indian company that manufactures and markets active ingredients (APIs), intermediates and nutrients for export. The company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. In addition to its generic business, the Company supports pharmaceutical companies through custom synthesis businesses in the commercialization of their proprietary products, from gram-scale requirements for clinical trials to launch and late life cycle management. The company's subsidiaries are Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.